{"artifact":{"id":"open_question-therapeutics-293e61a4","artifact_type":"open_question","entity_ids":"[\"therapeutics\"]","title":"Can interventions that reduce reliance on habitual performance (e.g., increasing voluntary/goal-directed control) delay or prevent PD onset in high-risk individuals?","quality_score":0.725,"created_by":"open_question_miner_papers","provenance_chain":"[]","content_hash":"63285eefd1386cae7effa69200a1ae309adca457920699c0e653afcc63ed568d","metadata":{"status":"open","_origin":{"url":null,"type":"external","tracked_at":"2026-04-28T06:18:28.872150"},"field_tag":"therapeutics","source_id":"31053241","source_doi":"10.1016/j.tins.2019.03.007","source_kind":"paper","question_hash":"293e61a4989d42f9","question_text":"Can interventions that reduce reliance on habitual performance (e.g., increasing voluntary/goal-directed control) delay or prevent PD onset in high-risk individuals?","importance_elo":1500,"_schema_version":1,"source_paper_id":"paper-10_1016_j_tins_2019_03_007","evidence_summary":"when combined with other more general risk factors, could explain the selective neurodegeneration","tractability_score":0.55,"potential_impact_score":0.9,"is_answerable_in_principle":true},"created_at":"2026-04-27T23:18:28.872226-07:00","updated_at":"2026-04-27T23:18:28.872226-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"external","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"ea02fd6c-8991-499c-8058-2de64e0735a0","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"open_question_miner_papers"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"open_question-therapeutics-293e61a4","is_canonical":true,"supersede_chain":["open_question-therapeutics-293e61a4"]}